SLDB Документы SEC - Solid Biosciences Inc.- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

CIK

1707502

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Solid Biosciences Inc.

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

August 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc.
June 13, 2025	EX-99.1	Amended and Restated 2020 Equity Incentive Plan, as amended Exhibit 99.1 SOLID BIOSCIENCES INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this Amended and Restated 2020 Equity Incentive Plan (the “Plan”) of Solid Biosciences Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make
June 13, 2025	8-K	FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 5.07 Submission of Matters to a Vote of Security Holders. Item 9.01 Financial S UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Solid Biosciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission Fi
June 13, 2025	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Solid Biosciences Inc.
June 13, 2025	S-8	As filed with the Securities and Exchange Commission on June 13, 2025 As filed with the Securities and Exchange Commission on June 13, 2025 Registration No.
June 13, 2025	EX-4.1	Certificate of Incorporation of Solid Biosciences Inc., as amended (incorporated herein by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-8 (File No. 333-288022) filed with the Securities and Exchange Commission on June 13, 2025). Exhibit 4.1 CERTIFICATE OF INCORPORATION OF SOLID BIOSCIENCES INC. The undersigned, for purposes of incorporating a corporation under the General Corporation Law of the State of Delaware, does hereby certify as follows: ARTICLE I NAME The name of the Corporation is: Solid Biosciences Inc. (the “Corporation”). ARTICLE II REGISTERED OFFICE AND AGENT The address of the Corporation’s registered office
May 22, 2025	CORRESP	May 22, 2025 May 22, 2025 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Daniel Crawford Re: Solid Biosciences Inc.
May 15, 2025	EX-4.5	Form of Subordinated Indenture EX-4.5 Exhibit 4.5 SOLID BIOSCIENCES INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a
May 15, 2025	424B5	$85,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277871 PROSPECTUS SUPPLEMENT (To Prospectus dated May 17, 2024) $85,000,000 Common Stock We previously entered into a Sales Agreement, dated March 13, 2019, with Jefferies LLC, or Jefferies, which was amended and restated on March 13, 2024, or the sales agreement, relating to the sale of shares of our common stock. In accordan
May 15, 2025	EX-4.7	Form of Subordinated Note EX-4.7 Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER N
May 15, 2025	S-3	As filed with the Securities and Exchange Commission on May 15, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on May 15, 2025 Registration No.
May 15, 2025	EX-4.4	Form of Senior Indenture Exhibit 4.4 SOLID BIOSCIENCES INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b)
May 15, 2025	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Solid Biosciences Inc.
May 15, 2025	EX-4.6	Form of Senior Note EX-4.6 Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE
May 15, 2025	8-K	FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Solid Biosciences Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission Fil
May 15, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc.
April 25, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 25, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
April 11, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
March 12, 2025	CORRESP	March 12, 2025 CORRESP March 12, 2025 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Tyler Howes Re: Solid Biosciences Inc.
March 12, 2025	CORRESP	March 12, 2025 CORRESP March 12, 2025 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Tyler Howes Re: Solid Biosciences Inc.
March 6, 2025	EX-10.51	Asset Purchase Agreement, dated as of September 19, 2024, by and between Solid Biosciences Inc. and FA212 LLC Exhibit 10.51 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Dated as of September 19, 2024 by and between SOLID BIOSCIENCES INC. and FA212 LLC TABLE OF CONTENTS ARTICLE I DEFINITIONS; INTERPRETATION 1
March 6, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38360 Solid Bioscienc
March 6, 2025	EX-10.10	Summary of Non-Employee Director Compensation Program Exhibit 10.10 SOLID BIOSCIENCES INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The non-employee directors of Solid Biosciences Inc. (the “Company”) shall receive the following compensation for their service as members of the Board of Directors of the Company (the “Board”). Director Compensation Our goal is to provide compensation for our non-employee directors in a manner that enables us to attrac
March 6, 2025	S-3	As filed with the Securities and Exchange Commission on March 6, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 6, 2025 Registration No.
March 6, 2025	EX-19.1	Insider Trading Policy. Exhibit 19.1 SOLID BIOSCIENCES INC. INSIDER TRADING POLICY 1. BACKGROUND AND PURPOSE 1.1 Why Have We Adopted This Policy? The federal securities laws prohibit any employee, officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the “Exchange Act”), an “executive officer”) or member of the Board of Directors (a “Director”) of Solid Biosciences Inc. (together with its subsid
March 6, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Solid Biosciences Inc.
March 6, 2025	EX-10.50	Research, Collaboration & License Agreement, dated as of November 4, 2020, by and between the Trustees of the University of Pennsylvania and FA212 LLC, as amended Exhibit 10.50 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. RESEARCH, COLLABORATION & LICENSE AGREEMENT DATED AS OF NOVEMBER 4, 2020 BY AND BETWEEN THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA AND F
March 6, 2025	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Solid Biosciences Inc.
March 6, 2025	EX-10.14	Executive Chair Agreement, effective January 1, 2022, by and between Solid Biosciences Inc. and Ian F. Smith, as amended by the First Amendment to Executive Chair Agreement, effective September 30, 2022, Second Amendment to the Executive Chair Agreement, effective January 1, 2024, and Third Amendment to the Executive Chair Agreement, effective January 6, 2025. Exhibit 10.14 Solid Biosciences Inc. Executive Chairman Agreement EXECUTIVE CHAIR AGREEMENT This Executive Chair Agreement (together with Exhibit A, the “Agreement”), effective January 1, 2022 (the “Effective Date”), is by and between Ian F. Smith, an individual having an address at 45 Commonwealth Avenue, Unit 3, Boston, MA 02116 (the “Executive Chair”), and Solid Biosciences Inc., a Delaware cor
March 6, 2025	S-3	As filed with the Securities and Exchange Commission on March 6, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on March 6, 2025 Registration No.
March 6, 2025	S-8	As filed with the Securities and Exchange Commission on March 6, 2025 As filed with the Securities and Exchange Commission on March 6, 2025 Registration No.
March 6, 2025	EX-21.1	Subsidiaries of Solid Biosciences Inc. Exhibit 21.1 Subsidiaries of Solid Biosciences Inc. Name of Subsidiary Jurisdiction of Organization AavantiBio, Inc. Delaware Solid Biosciences Securities Corporation Massachusetts
March 6, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Solid Biosciences Inc.
February 25, 2025	EX-1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.
February 21, 2025	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex-99-02212025090204.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 21, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State
February 18, 2025	FWP	SOLID BIOSCIENCES INC. Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock Issuer Free Writing Prospectus dated February 18, 2025 Filed Pursuant to Rule 433 Registration No.
February 18, 2025	EX-99.1	Solid Biosciences Announces Pricing of Underwritten Offering Exhibit 99.1 Solid Biosciences Announces Pricing of Underwritten Offering CHARLESTOWN, Massachusetts, February 18, 2025 – Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the pricing of an underwritten offering of 35,739,810 shares of its common stock at an offeri
February 18, 2025	EX-99.1	Cautionary Note Regarding Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and pro Exhibit 99.1 February 2025 SGT-003 INSPIRE DUCHENNE DATA UPDATE © 2025 Solid Biosciences Cautionary Note Regarding Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the Company; the ability to successfully achieve a
February 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Solid Bioscienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commissio
February 18, 2025	EX-4.1	Form of Pre-Funded Warrant Exhibit 4.1 SOLID BIOSCIENCES INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: February [ ], 2025 Solid Biosciences Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered
February 18, 2025	424B5	35,739,810 Shares of Common Stock Pre-Funded Warrants to Purchase 13,888,340 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277871 PROSPECTUS SUPPLEMENT (to Prospectus dated May 17, 2024) 35,739,810 Shares of Common Stock Pre-Funded Warrants to Purchase 13,888,340 Shares of Common Stock We are offering 35,739,810 shares of our common stock in this offering and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purc
February 18, 2025	EX-1.1	Underwriting Agreement, dated February 18, 2025, by and among the Company and Jefferies LLC and Leerink Partners LLC Exhibit 1.1 SOLID BIOSCIENCES INC. 35,739,810 Shares of Common Stock, Par Value $0.001 and Pre-Funded Warrants to Purchase 13,888,340 Shares of Common Stock Underwriting Agreement February 18, 2025 Jefferies LLC Leerink Partners LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Leerink Partners LLC 53 St
February 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Solid Bioscienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commissio
February 18, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 18, 2025 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commissio
February 14, 2025	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2025 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers").
November 14, 2024	SC 13D/A	SLDB / Solid Biosciences Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d877672dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Solid Biosciences Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83422E204 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (6
November 14, 2024	SC 13G/A	SLDB / Solid Biosciences Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
November 14, 2024	EX-99	JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99 2 p24-3214exhibit99.htm JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned
November 14, 2024	SC 13G	SLDB / Solid Biosciences Inc. / Vestal Point Capital, LP - SOLID BIOSCIENCES INC. Passive Investment SC 13G 1 p24-3214sc13g.htm SOLID BIOSCIENCES INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Solid Biosciences Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 83422E204 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check t
November 12, 2024	SC 13G/A	SLDB / Solid Biosciences Inc. / Invus Global Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 d839083dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Solid Biosciences Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 83422E204 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Che
November 12, 2024	SC 13G/A	SLDB / Solid Biosciences Inc. / Adage Capital Management, L.P. - SOLID BIOSCIENCES INC. Passive Investment SC 13G/A 1 p24-3027sc13ga.htm SOLID BIOSCIENCES INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Solid Biosciences Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83422E204 (CUSIP Number) September 30, 2024** (Date of Event Which Requires Filing of This Statement)
November 12, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d839083dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the securities of Solid Biosciences Inc. is, and any amendments thereto signed by each or any of the undersigned shall be, filed on behalf of each of such person pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange
November 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc.
November 1, 2024	SC 13G/A	SLDB / Solid Biosciences Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 SLDBSC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) SOLID BIOSCIENCES INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 83422E204 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the approp
August 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc.
August 2, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d786855dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the securities of Solid Biosciences Inc. is, and any amendments thereto signed by each or any of the undersigned shall be, filed on behalf of each of such person pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange
August 2, 2024	SC 13G/A	SLDB / Solid Biosciences Inc. / Invus Global Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 d786855dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) Solid Biosciences Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 83422E204 (CUSIP Number) July 25, 2024 (Date of Event Which Requires Filing of this Statement) Check th
June 12, 2024	SC 13D/A	SLDB / Solid Biosciences Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Solid Biosciences Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 83422E 105 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.7
June 11, 2024	EX-99.1	Amended and Restated 2020 Equity Incentive Plan, as amended Exhibit 99.1 SOLID BIOSCIENCES INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this Amended and Restated 2020 Equity Incentive Plan (the “Plan”) of Solid Biosciences Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make
June 11, 2024	S-8	As filed with the Securities and Exchange Commission on June 11, 2024 As filed with the Securities and Exchange Commission on June 11, 2024 Registration No.
June 11, 2024	SC 13D/A	SLDB / Solid Biosciences Inc. / BCLS SB Investco, LP - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.
June 11, 2024	EX-4.1	Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-8 filed with the SEC on June 11, 2024) Exhibit 4.1 CERTIFICATE OF INCORPORATION OF SOLID BIOSCIENCES INC. The undersigned, for purposes of incorporating a corporation under the General Corporation Law of the State of Delaware, does hereby certify as follows: ARTICLE I NAME The name of the Corporation is: Solid Biosciences Inc. (the “Corporation”). ARTICLE II REGISTERED OFFICE AND AGENT The address of the Corporation’s registered office
June 11, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 Solid Biosciences Inc. (Exact name of registrant as specified in its charter) Delaware 001-38360 90-0943402 (State or other jurisdiction of incorporation) (Commission Fil
June 11, 2024	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Solid Biosciences Inc.
June 5, 2024	SC 13G	SLDB / Solid Biosciences Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 SLDBSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SOLID BIOSCIENCES INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 83422E204 (CUSIP Number) MAY 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the r
May 15, 2024	10-Q	` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc.
May 15, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Solid Biosciences Inc.
May 15, 2024	CORRESP	May 15, 2024 May 15, 2024 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Jimmy McNamara Re: Solid Biosciences Inc.
May 15, 2024	S-3/A	As filed with the Securities and Exchange Commission on May 15, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 15, 2024 Registration No.
May 15, 2024	EX-10.2	Employment Agreement, dated January 9, 2023, by and between Solid Biosciences Inc. and Kevin Tan Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of January 9, 2023 (the “Effective Date”) by and between Solid Biosciences Inc. (the “Company”) and Kevin Tan (the “Executive”) (together, the “Parties”). RECITALS WHEREAS, the Company desires to employ the Executive as its Chief Financial Officer and Treasurer; and WHEREAS, the Executive has agreed to accept
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 12, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
March 13, 2024	EX-97.1	Dodd-Frank Compensation Recovery Policy Exhibit 97.1 SOLID BIOSCIENCES INC. Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Solid Biosciences Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Dodd-Frank W
March 13, 2024	EX-10.30	Amended and Restated Sales Agreement, dated March 13, 2024, by and between the Company and Jefferies LLC (incorporated by reference to Exhibit 10.30 to the Annual Report on Form 10-K filed on March 13, 2024). Exhibit 10.30 SOLID BIOSCIENCES INC. Shares of Common Stock (par value $0.001 per share) AMENDED AND RESTATED SALES AGREEMENT March 13, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Solid Biosciences Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies
March 13, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38360 Solid Bioscienc
March 13, 2024	EX-10.55	License Agreement, dated as of June 23, 2016, by and between Solid GT, LLC and President and Fellows of Harvard College. Exhibit 10.55 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AGREEMENT This License Agreement is entered into as of this 23rd day of June, 2016 (the “Effective Date”), by and between Solid GT, LLC, a company org
March 13, 2024	EX-10.49	2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.49 to the Annual Report on Form 10-K filed on March 13, 2024). Exhibit 10.49 Solid Biosciences Inc. 2024 INDUCEMENT STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2024 Inducement Stock Incentive Plan (the “Plan”) of Solid Biosciences Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributi
March 13, 2024	EX-10.8	License Agreement, dated as of October 15, 2015, by and between Solid GT, LLC and The Curators of the University of Missouri. Exhibit 10.8 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AGREEMENT THIS LICENSE AGREEMENT (“AGREEMENT”) is made and entered into this 15th day of October 2015 (“EFFECTIVE DATE”), by and between THE CURATORS O
March 13, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Solid Biosciences Inc.
March 13, 2024	EX-10.53	Patent License Agreement, dated as of March 10, 2016, by and between Solid GT, LLC and the Regents of the University of Michigan. Exhibit 10.53 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. PATENT LICENSE AGREEMENT This Agreement is effective as of March 10, 2016 (the “EFFECTIVE DATE”), between Solid GT, LLC (“LICENSEE”) having the address in Art
March 13, 2024	EX-4.4	Form of Senior Indenture Exhibit 4.4 SOLID BIOSCIENCES INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inappl
March 13, 2024	EX-10.50	Form of Non-Statutory Stock Option Agreement under the 2024 Inducement Stock Incentive Plan. Exhibit 10.50 SOLID BIOSCIENCES INC. NONSTATUTORY STOCK OPTION AGREEMENT Granted under 2024 Inducement Stock Incentive Plan Solid Biosciences Inc. (the “Company”) hereby grants the following stock option pursuant to its 2024 Inducement Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Number of s
March 13, 2024	S-8	As filed with the Securities and Exchange Commission on March 13, 2024 As filed with the Securities and Exchange Commission on March 13, 2024 Registration No.
March 13, 2024	EX-10.15	Executive Chair Agreement, effective January 1, 2022, by and between Solid Biosciences Inc. and Ian F. Smith, as amended by the First Amendment to Executive Chair Agreement, effective September 30, 2022, and Second Amendment to the Executive Chair Agreement, effective January 1, 2024 Exhibit 10.15 Solid Biosciences Inc. Executive Chairman Agreement EXECUTIVE CHAIR AGREEMENT This Executive Chair Agreement (together with Exhibit A, the “Agreement”), effective January 1, 2022 (the “Effective Date”), is by and between Ian F. Smith, an individual having an address at 45 Commonwealth Avenue, Unit 3, Boston, MA 02116 (the “Executive Chair”), and Solid Biosciences Inc., a Delaware cor
March 13, 2024	EX-10.7	Exclusive Patent License Agreement, dated as of October 16, 2015, by and between Solid GT, LLC and the University of Washington. Exhibit 10.7 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. EXCLUSIVE PATENT LICENSE AGREEMENT This exclusive patent license agreement (“Agreement”) is dated and effective as of the date of last signature (the “Effectiv
March 13, 2024	EX-10.51	Form of Restricted Stock Unit Agreement under the 2024 Inducement Stock Incentive Plan. Exhibit 10.51 SOLID BIOSCIENCES INC. Restricted Stock Unit Agreement Granted under 2024 Inducement Stock Incentive Plan Solid Biosciences Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2024 Inducement Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Numb
March 13, 2024	EX-4.5	Form of Subordinated Indenture Exhibit 4.5 SOLID BIOSCIENCES INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b)
March 13, 2024	EX-10.27	Amended and Restated 2021 Employee Stock Purchase Plan Exhibit 10.27 SOLID BIOSCIENCES INC. AMENDED AND RESTATED 2021 EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the Amended and Restated 2021 Employee Stock Purchase Plan of Solid Biosciences Inc. 1. Purpose. The purpose of the Plan is to provide eligible employees of the Company and its Designated Subsidiaries with opportunities to purchase shares of Common Stock through ac
March 13, 2024	EX-21.1	Subsidiaries of Solid Biosciences Inc. Exhibit 21.1 Subsidiaries of Solid Biosciences Inc. Name of Subsidiary Jurisdiction of Organization AavantiBio, Inc. Delaware Solid Biosciences Securities Corporation Massachusetts
March 13, 2024	EX-4.7	Form of Subordinated Note Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE
March 13, 2024	S-3	As filed with the Securities and Exchange Commission on March 13, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on March 13, 2024 Registration No.
March 13, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Solid Biosciences Inc.
March 13, 2024	EX-10.52	Form of Restricted Stock Unit Agreement under the 2020 Equity Incentive Plan. Exhibit 10.52 SOLID BIOSCIENCES INC. RESTRICTED STOCK UNIT AGREEMENT Solid Biosciences Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2020 Equity Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of restricted stock units (“RSUs”) granted: Vesting Start
March 13, 2024	EX-10.54	Life Technologies Cell Line License Agreement, dated as of November 20, 2016, by and between Solid Biosciences, LLC and Life Technologies Corporation. Exhibit 10.54 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LIFE TECHNOLOGIES CELL LINE LICENSE AGREEMENT This CELL LINE LICENSE AGREEMENT (the “AGREEMENT” or the “LICENSE”), effective as of November 20, 2016 (the “EFF
March 13, 2024	EX-4.6	Form of Senior Note Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE
March 13, 2024	EX-10.56	License Agreement, dated as of August 3, 2017, by and between Solid Biosciences, LLC and President and Fellows of Harvard College. Exhibit 10.56 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AGREEMENT This License Agreement is entered into as of this 3rd day of August, 2017 (the “Effective Date”), by and between Solid Biosciences, LLC, a c
February 7, 2024	SC 13G	US83422E2046 / Solid Biosciences Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - SOLID BIOSCIENCES INC. Passive Investment SC 13G 1 p24-0741sc13.htm SOLID BIOSCIENCES INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Solid Biosciences Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83422E204 (CUSIP Number) January 8, 2024 (Date of Event Which Requires Filing of This Statement) Check the a
February 6, 2024	CORRESP	February 6, 2024 February 6, 2024 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Jessica Dickerson Re: Solid Biosciences Inc.
January 30, 2024	S-3	As filed with the Securities and Exchange Commission on January 30, 2024 Table of Contents As filed with the Securities and Exchange Commission on January 30, 2024 Registration No.
January 30, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Solid Biosciences Inc.
January 22, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d169779dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common Stock, $0.001 par value per share, of Solid Biosciences Inc. is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Se
January 22, 2024	SC 13G	US83422E2046 / Solid Biosciences Inc / Artal International S.C.A. - SC 13G Passive Investment SC 13G 1 d169779dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) Solid Biosciences Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 83422E204 (CUSIP Number) January 11, 2024 (Date of Event Which Requires Filing of this Statement) Check the a
January 12, 2024	SC 13G	US83422E2046 / Solid Biosciences Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
January 12, 2024	SC 13D/A	SLDB / Solid Biosciences Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d705363dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Solid Biosciences Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83422E 105 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (
January 12, 2024	SC 13D/A	SLDB / Solid Biosciences Inc. / BCLS SB Investco, LP - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.
January 12, 2024	EX-99.P	AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.P 2 d672151dex99p.htm EX-99.P Exhibit P AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, as amended, to file this Schedule 13D (inclu
January 11, 2024	SC 13D/A	SLDB / Solid Biosciences Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* SOLID BIOSCIENCES INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83422E105 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Peter Ko
January 10, 2024	SC 13D/A	SLDB / Solid Biosciences Inc. / BCLS SB Investco, LP - SC 13D/A Activist Investment SC 13D/A 1 d134075dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 7) Solid Biosciences Inc. (Name of Issuer) Common Stock, $0.001 par value pe
January 8, 2024	EX-99.2	Solid Biosciences Announces $109 Million Private Placement Exhibit 99.2 Solid Biosciences Announces $109 Million Private Placement Charlestown, MA – January 8, 2024 - Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximatel
January 8, 2024	EX-99.1	Forward Looking Statement This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the company; the EX-99.1 42nd Annual J.P. Morgan Healthcare Conference January 2024 Exhibit 99.1 Forward Looking Statement This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the company; the ability to successfully achieve and execute on the company’s prioriti
January 8, 2024	EX-10.2	Form of Registration Rights Agreement, dated January 8, 2024, by and among Solid Biosciences Inc. and the other parties thereto (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on January 8, 2024). Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of January 8, 2024 by and among Solid Biosciences Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of January 8, 2024 (the “Purchase Agreement”). Capital
January 8, 2024	EX-4.1	Form on Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on January 8, 2024). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “SEC”) OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Solid Biosciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission
January 8, 2024	EX-10.1	Form of Securities Purchase Agreement, dated January 8, 2024, by and among Solid Biosciences Inc. and the other parties thereto (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on January 8, 2024). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of January 8, 2024 by and among Solid Biosciences Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. The Company and the Investors are executing and delive
November 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Solid Bioscienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commissio
November 15, 2023	EX-99.1	– Planning to initiate Phase 1/2 trial in pediatric DMD Patients – – First cohort to study patients 4 to < 6 years of age – EX-99.1 Exhibit 99.1 Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 November 14, 2023 – Planning to initiate Phase 1/2 trial in pediatric DMD Patients – – First cohort to study patients 4 to < 6 years of age – CHARLESTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developin
November 8, 2023	10-Q	` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc.
November 8, 2023	EX-10.1	Employment Agreement, dated October 2, 2023, by and between Solid Biosciences Inc. and Gabriel Brooks (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed on November, 8 2023). Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of the Effective Date by and between Solid Biosciences Inc. (the “Company”) and Gabriel Brooks (the “Executive”) (together, the “Parties”). RECITALS WHEREAS, the Parties desire to enter into an agreement whereby the Executive will be employed as an employee of the Company on the terms contained in this Agreeme
August 14, 2023	10-Q	m` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q m` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc.
August 14, 2023	EX-10.1	Executive Transition and Separation Agreement, dated as of May 22, 2023, between Solid Biosciences Inc. and Carl Morris Exhibit 10.1 EXECUTIVE TRANSITION AND SEPARATION AGREEMENT This Executive Transition and Separation Agreement (the “Agreement”) is made as of May 22, 2023 (the “Effective Date”) by and between Solid Biosciences Inc. (the “Company”) and Dr. Carl Morris (the “Executive”) (together, the “Parties”). WHEREAS, the Company and the Executive are parties to the Employment Agreement dated as of January 25,
August 14, 2023	EX-10.2	Consulting Agreement dated as of July 14, 2023, between Solid Biosciences Inc. and PHDL Consulting LLC Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (together with Exhibit A, the “Agreement”), is by and between PHDL Consulting LLC (the “Special Advisor”) and Solid Biosciences Inc., a Delaware corporation (together with its affiliates, the “Company”), having an address at 500 Rutherford Avenue, Third Floor, Charlestown, MA 02129. WHEREAS, Carl Morris, Manager to the Special Advisor (“M
June 9, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission Fil
June 6, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Solid Biosciences Inc.
June 6, 2023	EX-99.1	2021 Employee Stock Purchase Plan, as amended EX-99.1 Exhibit 99.1 AMENDMENT NO. 1 TO 2021 EMPLOYEE STOCK PURCHASE PLAN OF SOLID BIOSCIENCES INC. The 2021 Employee Stock Purchase Plan (the “Plan”) of Solid Biosciences Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. The second sentence of the first paragraph of the Pl
June 6, 2023	S-8	As filed with the Securities and Exchange Commission on June 6, 2023 S-8 As filed with the Securities and Exchange Commission on June 6, 2023 Registration No.
May 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 Solid Biosciences In UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission Fil
May 11, 2023	10-Q	` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc.
May 11, 2023	EX-10.2	Employment Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and David Tyronne Howton (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed on May 11, 2023). Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of September 29, 2022 by and between Solid Biosciences Inc. (the “Company”) and Ty Howton (the “Executive”) (together, the “Parties”). RECITALS WHEREAS, the Executive is currently employed by AavantiBio, Inc. (“AavantiBio”) pursuant to that certain Employment Agreement, dated as of March 4, 2021, by and betwee
April 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 23, 2023	EX-10	Standard Exclusive License Agreement With Know-How (Agreement No. A19111), dated as of March 17, 2020, by and between AavantiBio, Inc. and University of Florida Research Foundation, Incorporated, as amended on May 25, 2021 and August 23, 2022 (incorporated by reference to Exhibit 10.43 to the Annual Report on Form 10-K filed on March 23, 2023). Exhibit 10.43 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omission. STANDARD EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW Agreement No: A19111 TABLE OF CONTENTS Section 1 Definitions Section 2 Grant Section 3 Diligence Obligations
March 23, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38360 Solid Bioscienc
March 23, 2023	EX-10	Standard Exclusive License Agreement With Know-How (Agreement No. A19110), dated as of March 17, 2020, by and between AavantiBio, Inc. and University of Florida Research Foundation, Incorporated, as amended on August 23, 2022 (incorporated by reference to Exhibit 10.42 to the Annual Report on Form 10-K filed as on March 23, 2023). Exhibit 10.42 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omission. STANDARD EXCLUSIVE LICENSE AGREEMENT WITH KNOW-HOW Agreement No: A19110 TABLE OF CONTENTS Section 1 Definitions Section 2 Grant Section 3 Diligence Obligations
March 23, 2023	EX-FILING FEES	Calculation of Filing Fee Tables EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Solid Biosciences Inc.
March 23, 2023	EX-4	Exhibit 4.2 Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the securities of Solid Biosciences Inc. (“us,” “our,” “we” or the “Company”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is intended as a summary only and therefore is not a complete description.
March 23, 2023	EX-10	Executive Chair Agreement, effective January 1, 2022, by and between Solid Biosciences Inc. and Ian F. Smith, as amended by the First Amendment to Executive Chair Agreement, effective September 30, 2022. Exhibit 10.17 Solid Biosciences Inc. Executive Chairman Agreement EXECUTIVE CHAIR AGREEMENT This Executive Chair Agreement (together with Exhibit A, the “Agreement”), effective January 1, 2022 (the “Effective Date”), is by and between Ian F. Smith, an individual having an address at 45 Commonwealth Avenue, Unit 3, Boston, MA 02116 (the “Executive Chair”), and Solid Biosciences Inc., a Delaware cor
March 23, 2023	S-8	Power of Attorney (included on the signature pages of this registration statement) S-8 1 d480217ds8.htm S-8 As filed with the Securities and Exchange Commission on March 23, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Solid Biosciences Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 90-0943402 (State or Other Jurisdiction of Incorporation o
March 23, 2023	EX-21	Subsidiaries of Solid Biosciences Inc. Exhibit 21.1 Subsidiaries of Solid Biosciences Inc. Name of Subsidiary Jurisdiction of Organization AavantiBio, Inc. Delaware Solid Biosciences Securities Corporation Massachusetts
March 23, 2023	EX-10	Summary of Non-Employee Director Compensation Program. Exhibit 10.12 SOLID BIOSCIENCES INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The non-employee directors of Solid Biosciences Inc. (the “Company”) shall receive the following compensation for their service as members of the Board of Directors of the Company (the “Board”). Director Compensation Our goal is to provide compensation for our non-employee directors in a manner that enables us to attrac
March 23, 2023	424B5	$24,183,414 Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-258859 PROSPECTUS SUPPLEMENT (To Prospectus dated August 27, 2021) $24,183,414 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated August 27, 2021, filed as part of our registration statement on Form S-3 (File No. 333-258859), which we refer to as the Prior Prospectus. The Prior Prospect
March 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2023 Solid Biosciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2023 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission F
March 20, 2023	EX-99.1	Solid Biosciences Inc. Poster Presentation March 19, 2023 EX-99.1 Exhibit 99.1 Exhibit 99.1 SOLID BIO SCIENCES IGNITE DMD Phase I/II Study of SGT-001 Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy Roxana Donisa Dreghici1, J. Patrick Gonzalez1, Kristy J. Brown1, Carl A. Morris1, Perry Shieh2, Barry Byrne3 1 Solid Biosciences, Charlestown, MA; 2University of California at Los Angeles, Los Angeles, CA; 3University of Florida, Gainesville, FL D
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Solid Biosciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission F
February 13, 2023	SC 13G/A	SLDB / Solid Biosciences Inc / K2 PRINCIPAL FUND, L.P. Passive Investment SC 13G/A 1 SLDB13G20230213.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Rule 13d-102) Amendment No. 1 Under the Securities Exchange Act of 1934 Solid Biosciences Inc. (Name of Issuer) Common Stock $0.001 par value per share (Title of Class of Securities) 83422E105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement)
February 13, 2023	SC 13G/A	US83422E2046 / Solid Biosciences Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 10, 2023	SC 13G/A	SLDB / Solid Biosciences Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Solid Biosciences Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 83422E105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
February 3, 2023	SC 13D/A	SLDB / Solid Biosciences Inc / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Solid Biosciences Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83422E 105 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address a
February 2, 2023	CORRESP	February 2, 2023 CORRESP 1 filename1.htm February 2, 2023 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Tim Buchmiller Re: Solid Biosciences Inc. Registration Statement on Form S-3 File No. 333-269424 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Solid Biosc
January 26, 2023	S-3	As filed with the Securities and Exchange Commission on January 26, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on January 26, 2023 Registration No.
January 26, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Solid Biosciences Inc.
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 Solid Biosciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission
January 9, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Solid Biosciences Inc.
January 9, 2023	EX-99.2	Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer EX-99.2 3 d426001dex992.htm EX-99.2 Exhibit 99.2 Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer CHARLESTOWN, MA — January 9, 2023 — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the appointment of Kevin Tan, CFA, a seasoned industry professional, as Chief Financial Officer.
January 9, 2023	S-8	As filed with the Securities and Exchange Commission on January 9, 2023 S-8 As filed with the Securities and Exchange Commission on January 9, 2023 Registration No.
January 9, 2023	EX-99.1	2023 Expected To Be a Year of Transformation and Meaningful Advancements for Solid PIPELINE Opportunity to become a leading precision genetic medicines company within neuromuscular and cardiac genetic medicine PROCESS Differentiated CMC expertise, bu EX-99.1 2 d426001dex991.htm EX-99.1 Solid Biosciences 41st Annual J.P. Morgan Healthcare Conference JANUARY 12, 2023 Exhibit 99.1 Forward Looking Statement This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the company; the anticipated milesto
December 12, 2022	SC 13G	SLDB / Solid Biosciences Inc / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Solid Biosciences Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 83422E105 (CUSIP Number) December 02, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
December 12, 2022	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated December 12, 2022 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers").
December 6, 2022	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d364338dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.
December 6, 2022	SC 13D/A	SLDB / Solid Biosciences Inc / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Solid Biosciences Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83422E 105 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address and Teleph
December 5, 2022	SC 13D/A	SLDB / Solid Biosciences Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* SOLID BIOSCIENCES INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83422E105 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Peter Ko
December 5, 2022	EX-99.2	Report of Independent Auditors Exhibit 99.2 Report of Independent Auditors To the Stockholders and the Board of Directors of AavantiBio, Inc. Opinion We have audited the financial statements of AavantiBio, Inc. (the Company), which comprise the balance sheets as of December 31, 2021 and 2020, and the related statements of operations and comprehensive loss, changes in convertible preferred stock and stockholders? deficit and cas
December 5, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commissio
December 5, 2022	EX-99.3	INDEX TO CONDENSED FINANCIAL STATEMENTS Page Condensed Balance Sheets as of September 30, 2022 and December 31, 2021 (Unaudited) 2 Condensed Statements of Operations and Comprehensive Loss for the nine months ended September 30, 2022 and 2021 (Unaudi Exhibit 99.3 INDEX TO CONDENSED FINANCIAL STATEMENTS Page Condensed Balance Sheets as of September 30, 2022 and December 31, 2021 (Unaudited) 2 Condensed Statements of Operations and Comprehensive Loss for the nine months ended September 30, 2022 and 2021 (Unaudited) 3 Condensed Statements of Convertible Preferred Stock and Stockholders? Deficit for the nine months ended September 30, 2022 and 202
December 5, 2022	EX-99.M	AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D Exhibit M AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, as amended, to file this Schedule 13D (including amendments thereto) jointly on behalf of each such party.
December 5, 2022	EX-99.4	UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET (in thousands, except share and per share data) As of September 30, 2022 As of September 30, As of September 30, 2022 2022 Solid AavantiBio, Transaction Accounting Adjustments Pro Forma Biosciences Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Introduction On September 29, 2022, Solid Biosciences Inc. (the ?Company? or ?Solid?) entered into an Agreement and Plan of Merger (the ?Merger Agreement?) by and among the Company, Greenland Merger Sub LLC, a Delaware limited liability corporation and a wholly owned subsidiary of the Company (?Transitory Subsidiary?), and Aa
December 5, 2022	EX-99.1	Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement - Transactions create a precision genetic medicine company focused on neuromuscular and cardiac diseases, led by industry veteran Bo Cumbo - Exhibit 99.1 Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement - Transactions create a precision genetic medicine company focused on neuromuscular and cardiac diseases, led by industry veteran Bo Cumbo - - Company to leverage synergies and key assets, including product candidates for Duchenne muscular dystrophy, Friedreich?s ataxia, BAG3
December 5, 2022	SC 13D/A	SLDB / Solid Biosciences Inc / BCLS SB Investco, LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Rule 13d-101) Information to be Included in Statements Filed Pursuant to ? 240.
December 2, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Solid Biosciences Inc.
December 2, 2022	EX-4.1	Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-8 filed on December 2, 2022) EX-4.1 Exhibit 4.1 CERTIFICATE OF INCORPORATION OF SOLID BIOSCIENCES INC. The undersigned, for purposes of incorporating a corporation under the General Corporation Law of the State of Delaware, does hereby certify as follows: ARTICLE I NAME The name of the Corporation is: Solid Biosciences Inc. (the “Corporation”). ARTICLE II REGISTERED OFFICE AND AGENT The address of the Corporation’s registered
December 2, 2022	S-8	As filed with the Securities and Exchange Commission on December 2, 2022 S-8 As filed with the Securities and Exchange Commission on December 2, 2022 Registration No.
December 1, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Solid Bioscience UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission
December 1, 2022	EX-99.2	Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio - Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases - EX-99.2 Exhibit 99.2 Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio - Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases - CHARLESTOWN, Mass., December 1, 2022 – Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne)
December 1, 2022	EX-99.1	SOLID BIOSCIENCES INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN EX-99.1 Exhibit 99.1 SOLID BIOSCIENCES INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this Amended and Restated 2020 Equity Incentive Plan (the “Plan”) of Solid Biosciences Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected
November 10, 2022	10-Q	` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc.
November 7, 2022	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul
October 28, 2022	PREM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
October 28, 2022	EX-FILING FEES	Calculation of Filing Fee Tables Schedule 14A (Form Type) Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Exhibit 107 Calculation of Filing Fee Tables Schedule 14A (Form Type) Solid Biosciences Inc.
October 27, 2022	EX-3.1	Certificate of Amendment to Certificate of Incorporation of Solid Biosciences Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF SOLID BIOSCIENCES INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Solid Biosciences Inc. (hereinafter called the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: FIRST: A resolut
October 27, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 Solid Bioscience UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission
October 4, 2022	SC 13D/A	SLDB / Solid Biosciences Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* SOLID BIOSCIENCES INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83422E105 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Peter Ko
October 3, 2022	SC 13D/A	SLDB / Solid Biosciences Inc / BCLS SB Investco, LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to ? 240.
September 30, 2022	EX-10.2	Form of Support and Joinder Agreement (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on September 30, 2022). EXHIBIT 10.2 FORM OF SUPPORT AND JOINDER AGREEMENT This Support and Joinder Agreement (this ?Agreement?) is made and entered into as of , 2022, by and among AavantiBio, Inc., a Delaware corporation (the ?Company?), Solid Biosciences Inc., a Delaware corporation (?Parent?), and the undersigned stockholder (the ?Stockholder?) of the Company. Capitalized terms used herein but not otherwise defined sh
September 30, 2022	EX-10.4	Registration Rights Agreement, dated September 29, 2022, by and among Solid Biosciences Inc. and the persons party thereto (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed on September 30, 2022). EXHIBIT 10.4 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of September 29, 2022 by and among Solid Biosciences Inc., a Delaware corporation (the ?Company?), and the ?Investors? named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of September 29, 2022 (the ?Purchase Agreement?). C
September 30, 2022	EX-10.8	Executive Transition and Separation Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and Erin Powers Brennan (incorporated by reference to Exhibit 10.8 to the Current Report on Form 8-K filed on September 30, 2022). EXHIBIT 10.8 EXECUTIVE TRANSITION AND SEPARATION AGREEMENT This Executive Transition and Separation Agreement (the ?Agreement?) is made as of September 29, 2022 (the ?Effective Date?) by and between Solid Biosciences Inc. (the ?Company?) and Erin Powers Brennan (the ?Executive?) (together, the ?Parties?). WHEREAS, the Company and the Executive are parties to the Employment Agreement dated as of Ma
September 30, 2022	EX-10.5	Employment Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and Alexander Cumbo (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed on September 30, 2022). EXHIBIT 10.5 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made as of September 29, 2022 by and between Solid Biosciences Inc. (the ?Company?) and Bo Cumbo (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Executive is currently employed by AavantiBio, Inc. (?AavantiBio?) pursuant to that certain Employment Agreement, dated as of July 31, 2020, by and between
September 30, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commissi
September 30, 2022	EX-99.2	On September 30, 2022, Solid Biosciences Inc. published the following post on LinkedIn: Exhibit 99.2 On September 30, 2022, Solid Biosciences Inc. published the following post on LinkedIn: Today, Solid announced it has entered into a definitive merger agreement to acquire AavantiBio, Inc. and a securities purchase agreement for a concurrent $75 million private placement. See our press release for more info [Link to Press Release on Solid?s Website] On September 30, 2022, Solid Biosci
September 30, 2022	EX-10.9	Consulting Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and Erin Powers Brennan (incorporated by reference to Exhibit 10.9 to the Current Report on Form 8-K filed on September 30, 2022). EXHIBIT 10.9 CONSULTING AGREEMENT This Consulting Agreement (together with Exhibit A, the ?Agreement?), is by and between Erin Brennan (the ?Special Advisor?), and Solid Biosciences Inc., a Delaware corporation (together with its affiliates, the ?Company?), having an address at 500 Rutherford Avenue, Third Floor, Charlestown, MA 02129. WHEREAS, Special Advisor has been employed as the Chief Legal
September 30, 2022	EX-99.1	Solid Biosciences Business Update Call September 30, 2022 Exhibit 99.1 Solid Biosciences Business Update Call September 30, 2022 Presenters Caitlin Lowie - VP, Communications and IR, Solid Biosciences Ilan Ganot - Co-Founder, President and CEO, Solid Biosciences Bo Cumbo - President, Chief Executive Officer of AavantiBio Carl Morris - Chief Financial Officer, Solid Biosciences Jenny Marlow - Chief Scientific Officer, AavantiBio Steve DiPalma - Interim Ch
September 30, 2022	EX-10.3	Securities Purchase Agreement, dated September 29, 2022, by and among Solid Biosciences Inc. and the persons party thereto EXHIBIT 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of September 29, 2022 by and among Solid Biosciences Inc., a Delaware corporation (the ?Company?), and the Investors identified on Exhibit A attached hereto (each an ?Investor? and collectively the ?Investors?). RECITALS A. On or prior to the date hereof, (i) the Company has
September 30, 2022	EX-10.6	Executive Transition and Separation Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and Ilan Ganot (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed on September 30, 2022). EXHIBIT 10.6 EXECUTIVE TRANSITION AND SEPARATION AGREEMENT This Executive Transition and Separation Agreement (the ?Agreement?) is made as of September 29, 2022 (the ?Effective Date?) by and between Solid Biosciences Inc. (the ?Company?) and Ilan Ganot (the ?Executive?) (together, the ?Parties?). WHEREAS, the Company and the Executive are parties to the Employment Agreement dated as of January 25,
September 30, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commissi
September 30, 2022	EX-99.2	Forward-Looking Statements and Industry and Market Data This presentation and various remarks we make during this presentation contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including Exhibit 99.2 Strategic Update: Acquisition of AavantiBio and $75M PIPE September 30, 2022 ? 2022 Solid Biosciences 1 Forward-Looking Statements and Industry and Market Data This presentation and various remarks we make during this presentation contain ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding: future expe
September 30, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Solid Bioscien UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commissi
September 30, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 Solid Bioscien UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commissi
September 30, 2022	EX-2.1	Agreement and Plan of Merger, dated as of September 29, 2022, by and among the Registrant, Greenland Merger Sub LLC, AavantiBio, Inc. and, solely in his capacity as the Equityholder Representative, Doug Swirsky (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 30, 2022) EXHIBIT 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among SOLID BIOSCIENCES INC., GREENLAND MERGER SUB LLC, AAVANTIBIO, INC., and, SOLELY IN HIS CAPACITY AS COMPANY EQUITYHOLDER REPRESENTATIVE, DOUG SWIRSKY Dated as of September 29, 2022 TABLE OF CONTENTS ARTICLE I THE MERGER 2 1.1 Merger; Effective Time of the Merger 2 1.2 Closing; Actions at the Closing 3 1.3 Effects of the Merger
September 30, 2022	EX-10.1	Form of Parent Support Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on September 30, 2022). EXHIBIT 10.1 FORM OF PARENT SUPPORT AGREEMENT This Support Agreement (this ?Agreement?) is made and entered into as of , 2022, by and among AavantiBio, Inc., a Delaware corporation (the ?Company?), Solid Biosciences Inc., a Delaware corporation (?Parent?), and the undersigned stockholder (the ?Stockholder?) of Parent. Capitalized terms used herein but not otherwise defined shall have the respectiv
September 30, 2022	EX-99.1	Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement - Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current A EXHIBIT 99.1 Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement - Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo - - Strong synergies expected by combining key assets, including product candidates for Duchenne muscular dystrop
September 30, 2022	EX-10.7	Consulting Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and Ilan Ganot (incorporated by reference to Exhibit 10.7 to the Current Report on Form 8-K filed on September 30, 2022). EXHIBIT 10.7 CONSULTING AGREEMENT This Consulting Agreement (together with Exhibit A, the ?Agreement?), is by and between Ilan Ganot (the ?Special Advisor?), and Solid Biosciences Inc., a Delaware corporation (together with its affiliates, the ?Company?), having an address at 500 Rutherford Avenue, Third Floor, Charlestown, MA 02129. WHEREAS, Special Advisor has been employed as the Chief Executiv
September 6, 2022	SC 13D/A	SLDB / Solid Biosciences Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* SOLID BIOSCIENCES INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83422E105 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Peter Ko
September 2, 2022	SC 13D/A	SLDB / Solid Biosciences Inc / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Solid Biosciences Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83422E 105 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address a
September 1, 2022	SC 13G	SLDB / Solid Biosciences Inc / K2 PRINCIPAL FUND, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 Solid Biosciences Inc. (Name of Issuer) Common Stock, $0.001 (Title of Class of Securities) 83422E105 (CUSIP Number) August 29, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
August 18, 2022	SC 13D/A	SLDB / Solid Biosciences Inc / BCLS SB Investco, LP - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.
August 11, 2022	EX-10.1	Summary of Non-Employee Director Compensation Policy. Exhibit 10.1 SOLID BIOSCIENCES INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The non-employee directors of Solid Biosciences Inc. (the ?Company?) shall receive the following compensation for their service as members of the Board of Directors of the Company (the ?Board?). Director Compensation Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract
August 11, 2022	EX-99.1	Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results - Transition to transient transfection-based manufacturing process continues for SGT-001; Company expects to continue dosing patients in 2023 - - Development of next Exhibit 99.1 Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results - Transition to transient transfection-based manufacturing process continues for SGT-001; Company expects to continue dosing patients in 2023 - - Development of next-generation Duchenne gene therapy candidate SGT-003 continues; Company anticipates mid-2023 Investigational New Drug (IND) submission - -
August 11, 2022	10-Q	` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc.
August 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2022 Solid Biosciences Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission File
June 9, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission Fil
June 6, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission Fil
June 1, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Solid Biosciences Inc.
June 1, 2022	S-8	As filed with the Securities and Exchange Commission on June 1, 2022 As filed with the Securities and Exchange Commission on June 1, 2022 Registration No.
April 28, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 d350727ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com
April 28, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A 1 d350727ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox
April 27, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 22, 2022 Solid Biosciences Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission File
April 27, 2022	EX-99.1	Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy - IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transiti EX-99.1 2 d326843dex991.htm EX-99.1 Exhibit 99.1 Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy - IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scaled transient transfection-based manufacturing process - - Novel capsid de
April 27, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc.
April 15, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14
April 4, 2022	8-K	Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2022 Solid Biosciences Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission File
March 14, 2022	EX-21.1	Subsidiaries of Solid Biosciences Inc. Exhibit 21.1 Subsidiaries of Solid Biosciences Inc. Name of Subsidiary Jurisdiction of Organization Solid Biosciences UK Limited United Kingdom Solid Biosciences Securities Corporation Massachusetts
March 14, 2022	EX-10.18	Summary of Non-Employee Director Compensation Program. Exhibit 10.18 SOLID BIOSCIENCES INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The non-employee directors of Solid Biosciences Inc. (the ?Company?) shall receive the following compensation for their service as members of the Board of Directors of the Company (the ?Board?). Director Compensation Our goal is to provide compensation for our non-employee directors in a manner that enables us to attrac
March 14, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38360 Solid Bioscienc
March 14, 2022	EX-10.25	Executive Chair Agreement, effective January 1, 2022, by and between Solid Biosciences Inc. and Ian F. Smith. EX-10.25 5 sldb-ex1025669.htm EX-10.25 Exhibit 10.25 Solid Biosciences Inc. Executive Chairman Agreement EXECUTIVE CHAIR AGREEMENT This Executive Chair Agreement (together with Exhibit A, the “Agreement”), effective January 1, 2022 (the “Effective Date”), is by and between Ian F. Smith, an individual having an address at 45 Commonwealth Avenue, Unit 3, Boston, MA 02116 (the “Executive Chair”), and
March 14, 2022	EX-10.4	Employment Agreement, dated as of March 1, 2021, by and between Solid Biosciences Inc. and Erin Powers Brennan Exhibit 10.4 Employment Agreement with Erin Brennan On March 1, 2021, we entered into an employment agreement with Ms. Brennan, our Chief Legal Officer. Pursuant to her employment agreement, Ms. Brennan is being paid an annual base salary of $410,000 for 2021, which base salary will be reviewed by the board of directors from time to time and is subject to change in the discretion of the board of d
March 14, 2022	EX-10.26	2020 Equity Incentive Plan, as amended by Amendment No. 1 to 2020 Stock Incentive Plan. Exhibit 10.26 SOLID BIOSCIENCES INC. 2020 EQUITY INCENTIVE PLAN 1.Purpose The purpose of this 2020 Equity Incentive Plan (the ?Plan?) of Solid Biosciences Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the Company an
March 14, 2022	EX-10.3	Employment Agreement, dated as of January 25, 2019, by and between Solid Biosciences Inc. and Joel Schneider. Exhibit 10.3 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of January 25, 2019 by and between Solid Biosciences Inc. (the ?Company?), and Dr. Joel Schneider (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Company desires to continue to employ the Executive as its Chief Technology Officer and Head of Exploratory Research and Development; and WHEREAS
March 14, 2022	EX-10.37	Amendment No. 1 to Sublease, dated as of December 3, 2021, by and between Solid Biosciences, LLC and Twitter, Inc. Exhibit 10.37 FIRST AMENDMENT TO SUBLEASE THIS FIRST AMENDMENT TO SUBLEASE (?First Amendment?) is entered into as of December 3, 2021 (the ?First Amendment Effective Date?), by and between TWITTER, INC., a Delaware corporation (?Sublandlord?), and SOLID BIOSCIENCES, LLC, a Delaware limited liability company (?Subtenant?), with reference to the following facts: A.Sublandlord and Subtenant are parti
March 14, 2022	EX-10.28	Form of Restricted Stock Unit Agreement under the 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.28 to the Annual Report on Form 10-K filed on March 14, 2022). Exhibit 10.28 SOLID BIOSCIENCES INC. Restricted Stock Unit Agreement Solid Biosciences Inc. (the ?Company?) hereby grants the following restricted stock units pursuant to its 2020 Equity Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the ?Participant?): Grant Date: Number of restricted stock units (?RSUs?) granted: Vesting Start
February 14, 2022	SC 13G/A	SLDB / Solid Biosciences Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Solid Biosciences Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 83422E105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
February 14, 2022	SC 13G/A	SLDB / Solid Biosciences Inc / Boxer Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* SOLID BIOSCIENCES INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 83422E105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the
February 11, 2022	SC 13G/A	SLDB / Solid Biosciences Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 10, 2022	EX-99.1	Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates - Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy program (SGT-003) to IND submissi EX-99.1 2 d289427dex991.htm EX-99.1 Exhibit 99.1 Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates - Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy program (SGT-003) to IND submission; SGT-003 has demonstrated enhanced muscle tropism and microdystrophin expression - - Company enter
January 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2022 Solid Biosciences Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission Fil
November 3, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc.
November 3, 2021	EX-10	Sales Agreement, dated March 13, 2019, by and between the Registrant and Jefferies LLC, as amended by Amendment No. 1 to the Sales Agreement, dated August 16, 2021, by and between the Registrant and Jefferies LLC Exhibit 10.2 SOLID BIOSCIENCES INC. Shares of Common Stock (par value $0.001 per share) SALES AGREEMENT March 13, 2019 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Solid Biosciences Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent an
November 3, 2021	EX-10	2021 Employee Stock Purchase Plan Exhibit 10.1 SOLID BIOSCIENCES INC. 2021 EMPLOYEE STOCK PURCHASE PLAN The purpose of this 2021 Employee Stock Purchase Plan (this ?Plan?) is to provide eligible employees of Solid Biosciences Inc. (the ?Company?) and certain of its subsidiaries with opportunities to purchase shares of the Company?s common stock, $0.001 par value per share (the ?Common Stock?), commencing at such time and on such d
September 29, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 29, 2021 Solid Biosciences Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission F
September 27, 2021	8-K/A	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2021 Solid Biosciences Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission
September 23, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2021 Solid Biosciences Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission F
August 25, 2021	CORRESP	August 25, 2021 August 25, 2021 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Solid Biosciences Inc.
August 16, 2021	EX-4.6	Form of Senior Note EX-4.6 5 d191656dex46.htm EX-4.6 Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEP
August 16, 2021	EX-99.5	Form of Inducement Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 99.5 to the Registration Statement on Form S-8 filed on August 16, 2021). Exhibit 99.5 Draft SOLID BIOSCIENCES INC. RESTRICTED STOCK UNIT AGREEMENT Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) Solid Biosciences Inc. (the “Company”) hereby grants the following restricted stock units. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of restricted stock units (“RSU
August 16, 2021	EX-4.5	Form of Subordinated Indenture EX-4.5 4 d191656dex45.htm EX-4.5 Exhibit 4.5 SOLID BIOSCIENCES INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.
August 16, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 16, 2021 Solid Biosciences Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38360 90-0943402 (State or Other Jurisdiction of Incorporation) (Commission File
August 16, 2021	EX-10.1	Lease, dated June 15, 2021, between Solid Biosciences, Inc. and Hood Park LLC. Exhibit 10.1 LEASE LANDLORD: Hood Park LLC, a Massachusetts limited liability company TENANT: Solid Biosciences Inc., a Delaware corporation PREMISES: Hood Park, Charlestown, Massachusetts DATED: June 15, 2021 {W12939071.11} i TABLE OF CONTENTS ARTICLE CAPTION PAGE ARTICLE I 5 (A) SUBJECTS REFERRED TO: 5 (B) EXHIBITS 8 ARTICLE II 8 ARTICLE III 9 (A) TERM 9 (B) DELIVERY 9 (C) TENANT?S WORK 10 (D) G
August 16, 2021	EX-10.4	Form of Nonstatutory Inducement Stock Option Agreement. EX-10.4 3 sldb-ex10434.htm EX-10.4 Exhibit 10.4 SOLID BIOSCIENCES INC. NONSTATUTORY STOCK OPTION AGREEMENT Solid Biosciences Inc. (the “Company”) hereby grants the following stock option. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Number of shares of the Company’s Common Stock subject to this option (“Shares”):
August 16, 2021	EX-4.7	Form of Subordinated Note EX-4.7 6 d191656dex47.htm EX-4.7 Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO T
August 16, 2021	EX-99.4	Form of Nonstatutory Inducement Stock Option Agreement Exhibit 99.4 SOLID BIOSCIENCES INC. NONSTATUTORY STOCK OPTION AGREEMENT Solid Biosciences Inc. (the “Company”) hereby grants the following stock option. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Number of shares of the Company’s Common Stock subject to this option (“Shares”): Option exercise price per Share: N
August 16, 2021	S-3	As filed with the Securities and Exchange Commission on August 16, 2021 Table of Contents As filed with the Securities and Exchange Commission on August 16, 2021 Registration No.

SLDB / Solid Biosciences Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)